卡非佐米-来那度胺-地塞米松对比来那度胺-地塞米松治疗不适合自体干细胞移植的新诊断骨髓瘤患者(EMN20):一项随机、开放标签、多中心、3期试验
EMN20研究在意大利27个中心比较每周卡非佐米-来那度胺-地塞米松与来那度胺-地塞米松治疗不适合移植的新诊断骨髓瘤,因达雷妥尤单抗方案引入提前终止,随机82例。卡非佐米组2年MRD阴性率60% vs 0%(p<0·0001),中位PFS未达到 vs 20·9个月(HR 0·24)。
要点
- 卡非佐米组2年MRD阴性率60%(95%CI 43-74) vs 来那度胺-地塞米松组0%(0-9),p<0·0001。
- 中位PFS卡非佐米组未达到 vs 来那度胺-地塞米松组20·9个月,HR 0·24(95%CI 0·11-0·56),p=0·00084。
- 卡非佐米组最常见≥3级不良事件为中性粒细胞减少9例(22%)、血小板减少4例(10%)、腹泻4例(10%)。
核心结论
- 在样本量小于计划(因试验提前终止)的局限性下,每周卡非佐米联合来那度胺-地塞米松在不适合移植的新诊断骨髓瘤中首次显示高MRD阴性率。
- 卡非佐米-来那度胺-地塞米松组较高的MRD阴性率与相比来那度胺-地塞米松组的PFS优势相关。
- 毒性可预测且总体可控。
研究设计与样本
- 随机、开放标签、多中心、3期试验,在意大利27个中心开展。
- 纳入符合IMWG衰弱评分适合或中等适合、具有可测量病灶、ECOG体能状态<3的新诊断不适合移植骨髓瘤患者。
- 因意大利将达雷妥尤单抗-来那度胺-地塞米松引入一线治疗,试验在入组30%计划患者(101/340)后于2021年11月23日提前终止。
- 2019年11月14日至2021年11月23日,101例入组患者中82例被评估合格并随机分配至卡非佐米-来那度胺-地塞米松组(n=42)或来那度胺-地塞米松组(n=40)。
- 主要终点为治疗2年后二代测序(灵敏度10-5)检测的MRD阴性和无进展生存期,在意向治疗(ITT)人群中评估。
主要发现
- ITT人群82例中女性35例(43%)、男性47例(57%);数据截止2024年3月29日,中位随访35·2个月(IQR 30·3-38·7)。
- 2年MRD阴性率:卡非佐米-来那度胺-地塞米松组42例中25例(60%,95%CI 43-74) vs 来那度胺-地塞米松组40例中0例(0%,95%CI 0-9),p<0·0001。
- 中位PFS:卡非佐米-来那度胺-地塞米松组未达到(未达到-未达到) vs 来那度胺-地塞米松组20·9个月(15·7-未达到),HR 0·24(95%CI 0·11-0·56),p=0·00084。
- 卡非佐米-来那度胺-地塞米松组(41例)最常见≥3级不良事件:中性粒细胞减少9例(22%)、血小板减少4例(10%)、腹泻4例(10%)、心脏事件3例(7%)、感染3例(7%)、动脉性高血压2例(5%)。
- 来那度胺-地塞米松组(40例)最常见≥3级不良事件:中性粒细胞减少6例(15%)、皮疹4例(10%)。
关键数值与推荐
- 卡非佐米-来那度胺-地塞米松方案:28天周期,第1周期第1天卡非佐米20 mg/m2静脉注射,第1周期第8、15天56 mg/m2静脉注射,第2-12周期第1、8、15天56 mg/m2静脉注射,第13周期至随机后5年第1、15天56 mg/m2静脉注射。
- 来那度胺25 mg口服第1-21天,地塞米松40 mg口服第1、8、15、22天,均持续至疾病进展或不耐受。
- 来那度胺-地塞米松组接受28天周期,来那度胺和地塞米松剂量与卡非佐米-来那度胺-地塞米松组相同。
- 2年MRD阴性率:卡非佐米-来那度胺-地塞米松组60%(95%CI 43-74) vs 来那度胺-地塞米松组0%(95%CI 0-9),p<0·0001。
- 中位PFS:卡非佐米-来那度胺-地塞米松组未达到 vs 来那度胺-地塞米松组20·9个月(95%CI 15·7-未达到),HR 0·24(95%CI 0·11-0·56),p=0·00084。
临床怎么用
- 原文未据此给出推荐。
- 作者认为,在样本量小于计划的局限性下,结果首次显示每周卡非佐米联合来那度胺-地塞米松在不适合移植的新诊断骨髓瘤中具有高MRD阴性率。
- 作者认为,卡非佐米-来那度胺-地塞米松组较高的MRD阴性率与相比来那度胺-地塞米松组的PFS优势相关;毒性可预测且总体可控。
局限性
- 因试验提前中断,样本量小于计划。
- 试验在入组30%计划患者(101/340)后因达雷妥尤单抗-来那度胺-地塞米松引入意大利一线治疗而提前终止。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Before the introduction of daratumumab-lenalidomide-dexamethasone as a first-line treatment for patients with newly diagnosed transplant-ineligible multiple myeloma, lenalidomide-dexamethasone was a standard of care. We aimed to explore whether addition of the second-generation proteasome inhibitor carfilzomib to lenalidomide-dexamethasone improved the rates of measurable residual disease (MRD) negativity and progression-free survival. METHODS: EMN20 is a randomised, open-label, multicentre, phase 3 trial comparing weekly carfilzomib-lenalidomide-dexamethasone versus lenalidomide-dexamethasone in patients with newly diagnosed transplant-ineligible multiple myeloma, conducted in 27 centres in Italy. Key inclusion criteria included fit or intermediate-fit status according to the International Myeloma Working Group (IMWG) frailty score, measurable disease according to IMWG criteria, and Eastern Cooperative Oncology Group performance status lower than 3. Patients randomly assigned to the carfilzomib-lenalidomide-dexamethasone group received 28-day carfilzomib-lenalidomide-dexamethasone cycles (carfilzomib 20 mg/m2 intravenously on day 1 for cycle 1, followed by 56 mg/m2 intravenously on days 8 and 15 for cycle 1, then 56 mg/m2 intravenously on days 1, 8, and 15 for cycles 2-12, and 56 mg/m2 intravenously on days 1 and 15 from cycle 13 until 5 years after randomisation; lenalidomide 25 mg orally on days 1-21 until disease progression or intolerance; dexamethasone 40 mg orally on days 1, 8, 15, and 22 until disease progression or intolerance). Patients assigned to the lenalidomide-dexamethasone group received 28-day cycles with lenalidomide-dexamethasone (same dosing and schedule used in the carfilzomib-lenalidomide-dexamethasone group). Primary endpoints were MRD negativity by next-generation sequencing (sensitivity 10-5) after 2 years of treatment and progression-free survival; and were assessed in the intention-to-treat (ITT) population (all patients who were eligible to receive treatment and who were randomly assigned to one of the treatment groups). On Nov 23, 2021, after enrolling 30% of planned patients (101/340), the trial was prematurely stopped due to the introduction of daratumumab-lenalidomide-dexamethasone as a first-line treatment in Italy, which caused the lenalidomide-dexamethasone control group to no longer be considered a standard treatment. This trial is registered with ClinicalTrials.gov, NCT04096066, and study recruitment is complete. FINDINGS: Between Nov 14, 2019, and Nov 23, 2021, 82 of 101 enrolled patients were assessed for eligibility and were randomised to receive carfilzomib-lenalidomide-dexamethasone (n=42) or lenalidomide-dexamethasone (n=40). In the ITT population, 35 (43%) of 82 patients were female and 47 (57%) were male. At data cutoff (March 29, 2024), the median follow-up was 35·2 months (IQR 30·3-38·7). The 2-year MRD negativity rates were 25 (60% 95% CI 43-74) of 42 patients with carfilzomib-lenalidomide-dexamethasone versus 0 (0%; 0-9) of 40 patients with lenalidomide-dexamethasone (p<0·0001). Median progression-free survival was not reached (not reached-not reached) with carfilzomib-lenalidomide-dexamethasone versus 20·9 months (15·7-not reached) with lenalidomide-dexamethasone (hazard ratio 0·24 [95% CI 0·11-0·56], p=0·00084). One patient was excluded from the safety analysis because they died before starting treatment. The most frequent grade 3 or worse adverse events were neutropenia (nine [22%] of 41 patients), thrombocytopenia (four [10%]), diarrhoea (four [10%]), cardiac events (three [7%]), infections (three [7%]), and arterial hypertension (two [5%]) with carfilzomib-lenalidomide-dexamethasone, and neutropenia (six [15%] of 40) and skin rash (four [10%]) with lenalidomide-dexamethasone. The most common serious adverse event was SARS-CoV-2-related pneumonia in both the carfilzomib-lenalidomide-dexamethasone group (two [5%] of 41 patients) and lenalidomide-dexamethasone group (three [7%] of 40 patients). Treatment-emergent adverse events leading to death were observed in two patients in the carfilzomib-lenalidomide-dexamethasone (two SARS-CoV-2 infections) and four patients in the lenalidomide-dexamethasone group (one acute myocardial infraction, one heart failure, one septic shock, and one SARS-CoV-2 infection). INTERPRETATION: With the limitation of a smaller sample size than planned due to the trial's early interruption, these results, to our knowledge, showed for the first-time high rates of MRD negativity with weekly carfilzomib added to lenalidomide-dexamethasone in patients with transplantation-ineligible newly diagnosed multiple myeloma. In the carfilzomib-lenalidomide-dexamethasone group, higher MRD negativity rates were associated with a progression-free survival advantage over lenalidomide-dexamethasone. Toxicities were predictable and generally manageable. FUNDING: Amgen, Bristol Myers Squibb.
引用
- Bringhen S, Cani L, Antonioli E, et al. Carfilzomib-lenalidomide-dexamethasone versus lenalidomide-dexamethasone in patients with newly diagnosed myeloma ineligible for autologous stem-cell transplantation (EMN20): a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2025. PMID: 40769686. doi:10.1016/S2352-3026(25)00162-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。